• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Chloroquinolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Haloquinolines Chloroquinolines

Recent Advances in the Study of 3-Quinolinecarbonitrile,4-chloro-7-(trifluoromethyl)- (CAS: 157301-81-0)

The compound 3-Quinolinecarbonitrile,4-chloro-7-(trifluoromethyl)- (CAS: 157301-81-0) has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug development. This quinoline derivative is characterized by its unique structural features, including a chloro-substituent at the 4-position and a trifluoromethyl group at the 7-position, which contribute to its diverse biological activities. Recent studies have explored its role as a key intermediate in the synthesis of pharmacologically active molecules, particularly in the development of kinase inhibitors and antimicrobial agents.

One of the most notable advancements in the study of this compound is its application in the design of kinase inhibitors. Kinases play a crucial role in cellular signaling pathways, and their dysregulation is often associated with various diseases, including cancer and inflammatory disorders. Researchers have demonstrated that 3-Quinolinecarbonitrile,4-chloro-7-(trifluoromethyl)- can serve as a scaffold for the development of selective kinase inhibitors. For instance, a recent study published in the Journal of Medicinal Chemistry highlighted its use in the synthesis of novel EGFR (Epidermal Growth Factor Receptor) inhibitors, which showed promising antitumor activity in preclinical models.

In addition to its role in kinase inhibition, this compound has also been investigated for its antimicrobial properties. The trifluoromethyl group is known to enhance the lipophilicity and metabolic stability of molecules, making it a valuable moiety in antimicrobial drug design. A 2023 study in Bioorganic & Medicinal Chemistry Letters reported the synthesis of a series of derivatives based on 3-Quinolinecarbonitrile,4-chloro-7-(trifluoromethyl)-, which exhibited potent activity against drug-resistant bacterial strains, including MRSA (Methicillin-Resistant Staphylococcus aureus). These findings underscore the potential of this compound in addressing the growing challenge of antibiotic resistance.

The synthetic pathways for 3-Quinolinecarbonitrile,4-chloro-7-(trifluoromethyl)- have also been optimized in recent years. Advances in catalytic methods, such as palladium-catalyzed cross-coupling reactions, have enabled more efficient and scalable production of this compound. A 2022 publication in Organic Process Research & Development detailed a novel, high-yield synthesis route that minimizes the use of hazardous reagents and reduces environmental impact. These improvements are critical for facilitating the compound's broader application in pharmaceutical research and development.

Despite these promising developments, challenges remain in the clinical translation of derivatives based on 3-Quinolinecarbonitrile,4-chloro-7-(trifluoromethyl)-. Issues such as bioavailability, toxicity, and off-target effects need to be addressed through further structural optimization and in-depth pharmacological studies. However, the compound's versatility and the growing body of research supporting its utility suggest that it will continue to be a valuable tool in drug discovery. Future studies are expected to explore its potential in other therapeutic areas, such as neurodegenerative diseases and autoimmune disorders.

In conclusion, 3-Quinolinecarbonitrile,4-chloro-7-(trifluoromethyl)- (CAS: 157301-81-0) represents a promising scaffold in medicinal chemistry, with demonstrated applications in kinase inhibition and antimicrobial therapy. Recent advancements in synthetic methodologies and biological evaluations have further highlighted its potential. As research progresses, this compound is likely to play an increasingly important role in the development of novel therapeutic agents, addressing unmet medical needs in various disease areas.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)